[ad_1] Ema Chmp recommended the approval of a BRAF inhibitor, encorafenib, in combination with an MEK inhibitor, binimetinib, for the treatment of adult patients with melanoma with mutations BRAFV600 non-insoluble or metastatic. …
Read More »Melanoma BRAF- advanced mutation, positive opinion of the Chmp for still
